创新药企云顶新耀-B（01952.HK）今日盘中大跌5.07%，延续了昨日发布2024年度业绩后的跌势。尽管公司营收大幅增长，但亏损进一步扩大，引发市场担忧。
根据云顶新耀发布的2024年度业绩报告，公司实现营业收入7.07亿元人民币，同比增长461.16%。收入增长主要得益于依嘉®销售强劲增长及耐赋康®在中国大陆成功上市。然而，公司权益持有人应占年内亏损约10.41亿元，较上年同期的8.44亿元有所扩大。
值得注意的是，云顶新耀的分销及销售开支大幅增长119.9%，达5.08亿元。公司表示，这是由于扩大商业化团队和开展更多商业化活动所致。同时，研发支出略有下降，为5.28亿元。分析人士认为，高额的销售开支和持续扩大的亏损可能是导致投资者信心下降的主要原因，尽管公司在产品商业化方面取得了显著进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.